⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11428764 | 0.50 | — | — | |
| SCHEMBL3838429 | 0.50 | — | — | |
| SCHEMBL192491 | 0.50 | — | — | |
| SCHEMBL1355827 | 0.50 | — | — | |
| SCHEMBL8651273 | 0.50 | — | — | |
| SCHEMBL73637 | 0.50 | — | — | |
| SCHEMBL324377 | 0.50 | — | — | |
| SCHEMBL8434 | 0.47 | — | — | |
| SCHEMBL8585535 | 0.47 | — | — | |
| SCHEMBL24846 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11946050-B2 | Polynucleotide compositions and methods for gene expression regulations | APTAH BIO, INC. (US) | 2024-04-02 | — | — | US | claimed |
| WO-2023220744-A2 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-20230257745-A1 | Circular siRNAs | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | claimed |
| WO-2022011214-A1 | CIRCULAR SIRNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| EP-3919619-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| EP-1971690-B1 | TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS | TRANSLATIONAL THERAPEUTICS INC (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3324980-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017015109-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | claimed |
| US-8575123-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2013-11-05 | — | — | US | claimed |
| US-20130236968-A1 | MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20030119777-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | claimed |
| US-20030096784-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20030096287-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | IONIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20030096286-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20020165189-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| JP-2000510446-A | — | — | 2000-08-15 | — | — | JP | claimed |
| EP-0928290-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2000-01-19 | — | — | EP | claimed |
| EP-0928290-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-14 | — | — | EP | claimed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | claimed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | claimed |